EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION

During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention and early detection.

 

🔎 Key highlights:
In most developed countries, including Singapore, breast cancer is the most common cancer among women, surpassing colorectal and lung cancers. Early-stage detection leads to simpler, more effective treatments, while late detection often requires more complex and prolonged therapy.

+ Localized breast cancer: nearly 99% 5-year survival rate

+ Advanced breast cancer: only 29%

+ Early screening programs have reduced breast cancer mortality by up to 40%.

 

Next-generation screening: MCED (Multi-Cancer Early Detection)
Dr. Pang introduced blood-based MCED tests that analyze circulating tumor DNA (ctDNA) to detect early signals of 10 major cancer types (75 subtypes) — all from a single blood draw.

 

💗 October’s message – The Power of Awareness:
“Be proactive, not fearful. Awareness empowers prevention.”
Encouraging public participation and regular screening can help detect cancers earlier and improve survival outcomes.

 

👉 Let’s support each other — encourage your loved ones to take charge of their health and sign up for screening today.

 

👉  Watch the full live session here: https://www.facebook.com/watch/live/?ref=watch_permalink&v=2629044210778092

#MCED #EarlyDetection #CancerPrevention #BreastCancerAwareness #GeneSolutions

 

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More